<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h1>
  <ul>
<li>2021 Jan 14;7(1):3.</li>
<li>Sci Rep 15, 23495 (2025).</li>
<li>2014 Oct 21;121(5):664–672.</li>
<li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li>
<li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li>
<li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li>
<li>doi: 10.1038/s41572-020-00235-0.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html">Source</a> · 2025-09-08T15:00:00+00:00</p>
</body>
</html>